All In Biotech

Drug Trial Radar · NCT03920228

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

73

Actual

Start

Apr 1, 2019

Primary completion

Sep 19, 2020

Study completion Oct 19, 2020

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita. This study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of PTX-022 treatment.

Conditions

  • Pachyonychia Congenita

Interventions

  • PTX-022Drug

    PTX-022 QTORIN

  • PlaceboDrug

    Placebo topical

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient Global Assessment of Activities ScaleTime frame: 6 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Stanford University

    Palo Alto, California

  • Yale University

    New Haven, Connecticut

  • International Dermatology Research

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Oregon Health and Science University

    Portland, Oregon

  • Paddington Testing Co.

    Philadelphia, Pennsylvania

  • University of Utah

    Murray, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.